在Glucagon-Like-peptide-1受体的活性构成状态下增加胆固醇相互作用
在PubMed上查看摘要
概括
此摘要是机器生成的。胆固醇主要与葡萄糖类-1受体 (GLP-1R) 的活性形式相互作用. 这些发现揭示了胆固醇如何调节GLP-1R活性,为开发新代谢障碍疗法提供了洞察力.
科学领域
- 生物化学和分子药理学
- 膜蛋白动力学
- 脂质与蛋白质的相互作用
背景情况
- 葡萄糖类-1受体 (GLP-1R) 是一个B类G蛋白结合受体 (GPCR),对代谢调节至关重要.
- GLP- 1R是2型糖尿病和肥胖症的关键治疗点.
- 胆固醇在GLP-1R激活中的作用已知,但其在激活周期中的动态相互作用尚不清楚.
研究的目的
- 研究和描述不同结构状态的胆固醇与GLP-1R的相互作用.
- 了解胆固醇结合如何影响GLP-1R的活性和形状.
- 探索对胆固醇-GLP-1R相互作用的联体特异性影响.
主要方法
- 使用粗粒度分子动力学模拟.
- 分析了四种GLP- 1R构成状态中的胆固醇相互作用:无活性,部分活性,GLP- 1结合的活性和异性胺结合的活性.
- 量化胆固醇热点,相互作用能量和停留时间.
主要成果
- 胆固醇热点在GLP-1R结构状态之间有所不同,活性状态中的丰富度增加.
- 在活性GLP-1R状态下,胆固醇表现出更有利的相互作用能量和更长的停留时间.
- 在与GLP-1结合的活性状态和与exenatide结合的活性状态之间观察到微妙的胆固醇相互作用,这表明结合物的特异性.
结论
- 胆固醇对GLP-1R的活性构成具有增加的选择性.
- 在受体-脂质相互作用中,形态动力学起着重要作用.
- 了解这些脂质相互作用为代谢障碍的向药物治疗提供了潜在的途径.
相关概念视频
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

